Director’s orders

By Richard Lloyd

Under threat from investors and generic rivals, pharma and biotech have become staunch opponents of the inter partes review regime. However, as they push for reform, they face a stiff challenge from the US Patent and Trademark Office and Congress

As he sat in a board meeting of the Biotechnology Industry Organisation (BIO) in New York in February 2015, Ron Cohen noticed a new message on his phone. As CEO of Acorda Therapeutics, a biotech company worth around $900 million, Cohen is used to a steady stream of texts and emails making demands on his time. But this one was different. The message informed him that Kyle Bass – a hedge...

Issue 88

Take up a trial to IAM. Your three-week free trial would include:

  • Extensive access to the IAM site
  • The editor's weekly review by email
  • Free magazine issue delivered direct to you
Trial now Login

Register for more free content

  • Read more IAM blogs and articles
  • Receive the editor's weekly review by email
Register now  
Issue 88